Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. - Wikidata - wikimedia - TriplyDB

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

http://www.wikidata.org/entity/Q34613492

about

The microenvironment in breast cancer progression: biology and implications for treatment Bisphosphonates in breast cancer Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.Addressing the controversy: do bisphosphonates directly affect primary tumors?Tumour macrophages as potential targets of bisphosphonates.Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer Bone-targeted agents in the treatment of lung cancer.A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts.A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer.Zoledronic acid: multiplicity of use across the cancer continuum.Effects of bone-targeted agents on cancer progression and mortality.Dormancy in breast cancer.The Bone Microenvironment: a Fertile Soil for Tumor Growth.Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis.Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells.Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells.

P2860

Q26851314-0A560359-0116-4F78-8ABA-5F9D50272B12 Q26859326-C3EA3E4B-D8AC-41E2-B58B-F64A4E4CDCC2 Q30881569-45A6A05A-F057-45E4-B556-7DE5F3E752BE Q33739204-8B677081-168F-4ED9-823F-F7D76B7E9002 Q34024176-7226BFE7-4289-488E-9719-1C25F1BC2F7B Q34259906-C4EAEC37-38A3-4477-AB3B-60AA447546F0 Q34458449-DEAE9934-6558-4AC4-BD6E-0D8C3E319F6D Q34970986-F7DCF2D6-5B51-402B-B556-E52637783639 Q35547309-09A8E5F3-9F6A-4AAF-BAFD-7B87A78C7EFB Q35563128-9D56316A-107B-4841-B922-488EDD606156 Q35780792-CBF83F11-0B4B-42E8-A4D7-910E0AD6745F Q36491378-9D70125B-3BDD-4AC2-9CA8-6832C59E4AF5 Q37185494-D8628D56-43DF-408B-B176-EA4DE0DF5802 Q37499970-BBF3E51D-62D1-4728-B67A-2083E3B35DA7 Q37909355-BD7A82F3-71B1-401E-8590-8BE6E73224D3 Q38023206-9F7E03C8-3399-450A-8B27-B6B5BFEE7802 Q38173736-3BA2B39A-36A5-4D19-AC9C-F885D4C8AAC3 Q38851859-D40C21B4-2534-4012-9B36-7347980753C1 Q38990710-35E084A2-EDE8-40E7-A69A-AEDF95D2BE2D Q39555400-2D907469-462A-42A6-B88A-7806E49B71E0 Q46277856-71BAABFA-BCEE-4100-86DD-419CF8DF9217

P2860

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

http://www.wikidata.org/entity/Q34613492

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

@ast

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

@en

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

@nl

type

label

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

@ast

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

@en

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

@nl

prefLabel

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

@ast

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

@en

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

@nl

P1433

Q34613492-3202449D-1A36-42F3-92CA-76F564BF9F36

P1476

Q34613492-E3CD20CC-F5F0-4DAB-981A-C71B6994E98E

P2093

Q34613492-5ABE2C09-69E1-4542-BBB0-C7797C9093D7

P2860

Q34613492-00E8504D-2118-48E7-A314-0CA9683E5B4A

Q34613492-0150C838-B3F5-40E0-9257-C5A6E8B5B073

Q34613492-08F88192-BDBC-49FD-BC4D-608B26304831

Q34613492-0D38251F-89F1-437E-8BC9-B7B39D87DAFD

Q34613492-16B20E16-F40B-44EC-A8BA-C1F7090F7D41

Q34613492-17BC5DB6-3D0C-4981-A0C8-DB3B5ECA3590

Q34613492-22B6B084-2D02-4E85-9736-4D3C56D59A5E

Q34613492-23BB08D4-B38E-422F-98CB-57D68D8C6F1F

Q34613492-23D21ECF-DECF-48B1-869E-76E9D40C6A47

Q34613492-23E2AB0E-E02A-4E33-AF91-7A4504E0C183

P2888

Q34613492-78FC0E83-8BCE-4170-B873-3E918117962E

P304

Q34613492-6F6FDB06-EDCA-45C2-8383-2BABF6449E33

P31

Q34613492-4ac250b8-bfaf-40b9-874d-d9c12c2c5dcb

Q34613492-5E2796A2-7213-4EA8-8875-733715BA925D

P356

Q34613492-C67CBEBE-79E3-407D-BFAE-15BDFB3BE66F

P433

Q34613492-235CA0B1-83C1-45F0-8D58-6D03A1A1D12A

P478

Q34613492-68288839-21FB-4F5A-8002-2270339CE865

P50

Q34613492-AA7A0723-98DA-4BFC-A987-5ED2A27B5FE2

P577

Q34613492-3D1530FD-5402-4D62-A06B-CC60BDBB7F1B

P5875

Q34613492-123808C0-2F09-47C1-AA58-880D3E9A0CAA

P6179

Q34613492-47EBDD45-C454-49A2-8286-0300629BEDEE

P698

Q34613492-C9F1F79C-E272-4203-8E1C-D2BC389DC236

P921

Q34613492-251FF8EB-0DC5-455C-888D-2B4C5515CB75

Q34613492-32C9E18E-79FA-47A3-8996-1F435FC77112

Q34613492-67903F7A-1C22-4726-9131-4A54FD695483

Q34613492-71734DDD-2344-4183-B8E4-B438DBE18CD5

P932

Q34613492-4E631AE7-F66B-4248-9A54-6C6FD332D87C

P356

P1433

Breast Cancer Research

P1476

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer

@en

P2093

Robert E Coleman

http://www.w3.org/2001/XMLSchema#string

P2860

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Metastasis to bone: causes, consequences and therapeutic opportunities

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice.

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk.

Osteonecrosis of the jaw in a patient on Denosumab.

Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors

Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

P2888

P304

214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2769

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49700436

http://www.w3.org/2001/XMLSchema#string

P6179

1012736800

http://www.w3.org/2001/XMLSchema#string

P698

21176176

http://www.w3.org/2001/XMLSchema#string

P921

organophosphorus compound

breast neoplasm

biomedical investigative technique

P932

3046431

http://www.w3.org/2001/XMLSchema#string